Review



lc ms cpt wt h nps solutions  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Bio-Techne corporation lc ms cpt wt h nps solutions
    Schematic illustration of the PSMA and esterase dual responsive <t>CPT</t> nanoparticles <t>(CPT-WT-H</t> NPs) with negatively charged surface, prolonged blood circulation, excellent PSMA-targeted delivery, enhanced tumor accumulation, potent antitumor efficacy and low side effects.
    Lc Ms Cpt Wt H Nps Solutions, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 22 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lc+ms+cpt+wt+h+nps+solutions/Recombinant+Human+PSMA%2FFOLH1+Protein/pmc08650835-35-28-22
    Average 94 stars, based on 22 article reviews
    lc ms cpt wt h nps solutions - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery"

    Article Title: Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery

    Journal: International Journal of Nanomedicine

    doi: 10.2147/IJN.S331060

    Schematic illustration of the PSMA and esterase dual responsive CPT nanoparticles (CPT-WT-H NPs) with negatively charged surface, prolonged blood circulation, excellent PSMA-targeted delivery, enhanced tumor accumulation, potent antitumor efficacy and low side effects.
    Figure Legend Snippet: Schematic illustration of the PSMA and esterase dual responsive CPT nanoparticles (CPT-WT-H NPs) with negatively charged surface, prolonged blood circulation, excellent PSMA-targeted delivery, enhanced tumor accumulation, potent antitumor efficacy and low side effects.

    Techniques Used:

    Characterization of CPT-WT-H NPs. ( A ) A TEM image of CPT-WT-H NPs dispersed in PBS (pH 7.4); inserts are the photographs of CPT-WT-H NPs in PBS in bright field (left) and under UV light at 365 nm with a red laser passing through (right). ( B ) DLS histograms of CPT-WT-H NPs in PBS. ( C ) Change of hydrodynamic diameter (Dh) of CPT-WT-H NPs in PBS for 120 h. ( D ) Schematic of sequential PSMA hydrolysis of CPT-WT-H (CPT12A-βAsp-GluγGluγGluγGlu) to yield the PSMA hydrolysate CPT12A-βAsp. ( E ) Characterization of in vitro PSMA response of CPT-WT-H NPs by LC-MS.
    Figure Legend Snippet: Characterization of CPT-WT-H NPs. ( A ) A TEM image of CPT-WT-H NPs dispersed in PBS (pH 7.4); inserts are the photographs of CPT-WT-H NPs in PBS in bright field (left) and under UV light at 365 nm with a red laser passing through (right). ( B ) DLS histograms of CPT-WT-H NPs in PBS. ( C ) Change of hydrodynamic diameter (Dh) of CPT-WT-H NPs in PBS for 120 h. ( D ) Schematic of sequential PSMA hydrolysis of CPT-WT-H (CPT12A-βAsp-GluγGluγGluγGlu) to yield the PSMA hydrolysate CPT12A-βAsp. ( E ) Characterization of in vitro PSMA response of CPT-WT-H NPs by LC-MS.

    Techniques Used: In Vitro, Liquid Chromatography with Mass Spectroscopy

    In vitro cytotoxicity of CPT-WT-H NPs and CPT against PSMA-expressing (PSMA + ) cancer cell LNCaP-FGC ( A ) and non-PSMA-expressing (PSMA − ) cancer cells HepG2 ( B ), MCF-7 ( C ), HeLa ( D ), DU145 ( E ), PC-3 ( F ) and normal liver cells LO2 ( G ), the IC 50 values of CPT and CPT-WT-H NPs on different cell lines ( H ). *** p < 0.001, vs LNCaP-FGC cells.
    Figure Legend Snippet: In vitro cytotoxicity of CPT-WT-H NPs and CPT against PSMA-expressing (PSMA + ) cancer cell LNCaP-FGC ( A ) and non-PSMA-expressing (PSMA − ) cancer cells HepG2 ( B ), MCF-7 ( C ), HeLa ( D ), DU145 ( E ), PC-3 ( F ) and normal liver cells LO2 ( G ), the IC 50 values of CPT and CPT-WT-H NPs on different cell lines ( H ). *** p < 0.001, vs LNCaP-FGC cells.

    Techniques Used: In Vitro, Expressing

    Cellular uptake of CPT-WT-H NPs in vitro. ( A ) CLSM images of LNCaP-FGC (PSMA + ) cells incubated with CPT-WT-H NPs (10 μM) for 1 and 4 h. ( B ) CLSM images of HepG2 (PSMA − ) cells incubated with CPT-WT-H NPs (10 μM) for 1 and 4 h. Nuclei were stained by PI (red), the blue color was indicative of CPT. ( C ) Mean fluorescence intensity of CPT-WT-H NPs internalized by LNCaP-FGC and HepG2 cells after incubation for 1, and 4 h. *** p < 0.001. ( D ) Flow cytometry analysis for apoptosis of LNCaP-FGC (PSMA + ) (1) and HepG2 (PSMA − ) (2) cells induced by CPT-WT-H NPs for 72 h. Q1, necrotic cells; Q2, late apoptotic cells; Q3, living cells; Q4, early apoptotic cells. Inserted numbers in the profiles indicate the percentage of the cells present in this area.
    Figure Legend Snippet: Cellular uptake of CPT-WT-H NPs in vitro. ( A ) CLSM images of LNCaP-FGC (PSMA + ) cells incubated with CPT-WT-H NPs (10 μM) for 1 and 4 h. ( B ) CLSM images of HepG2 (PSMA − ) cells incubated with CPT-WT-H NPs (10 μM) for 1 and 4 h. Nuclei were stained by PI (red), the blue color was indicative of CPT. ( C ) Mean fluorescence intensity of CPT-WT-H NPs internalized by LNCaP-FGC and HepG2 cells after incubation for 1, and 4 h. *** p < 0.001. ( D ) Flow cytometry analysis for apoptosis of LNCaP-FGC (PSMA + ) (1) and HepG2 (PSMA − ) (2) cells induced by CPT-WT-H NPs for 72 h. Q1, necrotic cells; Q2, late apoptotic cells; Q3, living cells; Q4, early apoptotic cells. Inserted numbers in the profiles indicate the percentage of the cells present in this area.

    Techniques Used: In Vitro, Incubation, Staining, Fluorescence, Flow Cytometry

    In vivo NIRF imaging of DiR-doped CPT-WT-H NPs. ( A ) In vivo NIRF images of the MCF-7 tumor-bearing nude mice (PSMA-producing) after intravenous injection of free DiR (0.25 mg·mL −1 , 100 µL) or DiR-doped CPT-WT-H NPs (0.25 mg·mL −1 , 100 µL). ( B ) Integrated fluorescence intensity of tumor obtained after intravenous injection of DiR-doped CPT-WT-H NPs (0.25 mg·mL −1 , 100 µL). ( C ) Ex vivo NIRF images and ( D ) Integrated fluorescence intensity of the major organs and tumors excised at 48 h post intravenous injection of DiR-doped CPT-WT-H NPs, *** p < 0.001, vs tumor. ( E ) In vivo pharmacokinetics profiles of CPT-WT-H NPs s at the equivalent dose (30 mg·kg −1 ) in BALB/c mice. Error bars indicate SD (n = 6).
    Figure Legend Snippet: In vivo NIRF imaging of DiR-doped CPT-WT-H NPs. ( A ) In vivo NIRF images of the MCF-7 tumor-bearing nude mice (PSMA-producing) after intravenous injection of free DiR (0.25 mg·mL −1 , 100 µL) or DiR-doped CPT-WT-H NPs (0.25 mg·mL −1 , 100 µL). ( B ) Integrated fluorescence intensity of tumor obtained after intravenous injection of DiR-doped CPT-WT-H NPs (0.25 mg·mL −1 , 100 µL). ( C ) Ex vivo NIRF images and ( D ) Integrated fluorescence intensity of the major organs and tumors excised at 48 h post intravenous injection of DiR-doped CPT-WT-H NPs, *** p < 0.001, vs tumor. ( E ) In vivo pharmacokinetics profiles of CPT-WT-H NPs s at the equivalent dose (30 mg·kg −1 ) in BALB/c mice. Error bars indicate SD (n = 6).

    Techniques Used: In Vivo, Imaging, Injection, Fluorescence, Ex Vivo

    CPT-WT-H NPs significantly inhibited tumor progression and dramatically reduced side effects in an MCF-7 human breast cancer model. ( A ) The growth curves of MCF-7 tumor after treatment, which was initiated on day 13 post tumor inoculation, and drugs were intravenously injected every 2 days for 8 times (n = 6/group). ( B ) Changes of body weight in each group. ( C ) The tumor pictures in each group. ( D ) Excised tumor weight in each group. ( E ) Excised tumor volume in each group. * p < 0.05; *** p < 0.001. ( F ) Histological analysis of tumor sections stained with H&E.
    Figure Legend Snippet: CPT-WT-H NPs significantly inhibited tumor progression and dramatically reduced side effects in an MCF-7 human breast cancer model. ( A ) The growth curves of MCF-7 tumor after treatment, which was initiated on day 13 post tumor inoculation, and drugs were intravenously injected every 2 days for 8 times (n = 6/group). ( B ) Changes of body weight in each group. ( C ) The tumor pictures in each group. ( D ) Excised tumor weight in each group. ( E ) Excised tumor volume in each group. * p < 0.05; *** p < 0.001. ( F ) Histological analysis of tumor sections stained with H&E.

    Techniques Used: Injection, Staining

    Representative H&E-stained histological images obtained from liver ( A ) and kidneys ( B ) after intravenous administration of irinotecan (10 mg·kg −1 ) and CPT-WT-H NPs (10, 30, 60 mg·kg −1 ). The PBS-treated group and the untreated group were used as the control. (I: PBS, II: CPT-WT-H NPs (10mg·kg −1 ), III: CPT-WT-H NPs (30mg·kg −1 ), IV: CPT-WT-H NPs (60mg·kg −1 ), V: Irinotecan (10 mg·kg −1 ), VI: Normal group). ( C ) Blood biochemical analysis of after the antitumor efficacy evaluation. The PBS-treated group and the untreated group were used as the control. The main parameters of hepatic and renal function are alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), and creatinine (CRE). Error bars indicate SD (n = 6). * p < 0.05; *** p < 0.001.
    Figure Legend Snippet: Representative H&E-stained histological images obtained from liver ( A ) and kidneys ( B ) after intravenous administration of irinotecan (10 mg·kg −1 ) and CPT-WT-H NPs (10, 30, 60 mg·kg −1 ). The PBS-treated group and the untreated group were used as the control. (I: PBS, II: CPT-WT-H NPs (10mg·kg −1 ), III: CPT-WT-H NPs (30mg·kg −1 ), IV: CPT-WT-H NPs (60mg·kg −1 ), V: Irinotecan (10 mg·kg −1 ), VI: Normal group). ( C ) Blood biochemical analysis of after the antitumor efficacy evaluation. The PBS-treated group and the untreated group were used as the control. The main parameters of hepatic and renal function are alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), and creatinine (CRE). Error bars indicate SD (n = 6). * p < 0.05; *** p < 0.001.

    Techniques Used: Staining

    Related Articles

    In Vitro:

    Article Title: Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery
    Article Snippet: The ultraviolet-visible (UV-vis) absorption spectrum between 200 and 400 nm was measured by a UV-vis spectrophotometer (Hitachi, Japan). .. The in vitro PSMA response of the CPT-WT-H NPs was performed as described in the product catalog (Recombinant Human PSMA/FOLH1/NAALADase I, 4234-ZN, bio-techne, USA) with some modifications using LC-MS. CPT-WT-H NPs solutions (125 μL, 0.1 mg·mL −1 in HEPS buffer) were incubated with the rh-PSMA solution (125 μL, 1.0 μg·mL −1 in HEPS buffer) at 37°C for 2 h, 8 h, 12 h, 24 h and 48 h in a remonstrated oscillator (HZQ-QX, Harbin Donglian Instrument Co. Ltd., China). ..

    Recombinant:

    Article Title: Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery
    Article Snippet: The ultraviolet-visible (UV-vis) absorption spectrum between 200 and 400 nm was measured by a UV-vis spectrophotometer (Hitachi, Japan). .. The in vitro PSMA response of the CPT-WT-H NPs was performed as described in the product catalog (Recombinant Human PSMA/FOLH1/NAALADase I, 4234-ZN, bio-techne, USA) with some modifications using LC-MS. CPT-WT-H NPs solutions (125 μL, 0.1 mg·mL −1 in HEPS buffer) were incubated with the rh-PSMA solution (125 μL, 1.0 μg·mL −1 in HEPS buffer) at 37°C for 2 h, 8 h, 12 h, 24 h and 48 h in a remonstrated oscillator (HZQ-QX, Harbin Donglian Instrument Co. Ltd., China). ..

    Incubation:

    Article Title: Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery
    Article Snippet: The ultraviolet-visible (UV-vis) absorption spectrum between 200 and 400 nm was measured by a UV-vis spectrophotometer (Hitachi, Japan). .. The in vitro PSMA response of the CPT-WT-H NPs was performed as described in the product catalog (Recombinant Human PSMA/FOLH1/NAALADase I, 4234-ZN, bio-techne, USA) with some modifications using LC-MS. CPT-WT-H NPs solutions (125 μL, 0.1 mg·mL −1 in HEPS buffer) were incubated with the rh-PSMA solution (125 μL, 1.0 μg·mL −1 in HEPS buffer) at 37°C for 2 h, 8 h, 12 h, 24 h and 48 h in a remonstrated oscillator (HZQ-QX, Harbin Donglian Instrument Co. Ltd., China). ..



    Similar Products

    94
    Bio-Techne corporation lc ms cpt wt h nps solutions
    Schematic illustration of the PSMA and esterase dual responsive <t>CPT</t> nanoparticles <t>(CPT-WT-H</t> NPs) with negatively charged surface, prolonged blood circulation, excellent PSMA-targeted delivery, enhanced tumor accumulation, potent antitumor efficacy and low side effects.
    Lc Ms Cpt Wt H Nps Solutions, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lc+ms+cpt+wt+h+nps+solutions/Recombinant+Human+PSMA%2FFOLH1+Protein/pmc08650835-35-28-22
    Average 94 stars, based on 1 article reviews
    lc ms cpt wt h nps solutions - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    Image Search Results


    Schematic illustration of the PSMA and esterase dual responsive CPT nanoparticles (CPT-WT-H NPs) with negatively charged surface, prolonged blood circulation, excellent PSMA-targeted delivery, enhanced tumor accumulation, potent antitumor efficacy and low side effects.

    Journal: International Journal of Nanomedicine

    Article Title: Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery

    doi: 10.2147/IJN.S331060

    Figure Lengend Snippet: Schematic illustration of the PSMA and esterase dual responsive CPT nanoparticles (CPT-WT-H NPs) with negatively charged surface, prolonged blood circulation, excellent PSMA-targeted delivery, enhanced tumor accumulation, potent antitumor efficacy and low side effects.

    Article Snippet: The in vitro PSMA response of the CPT-WT-H NPs was performed as described in the product catalog (Recombinant Human PSMA/FOLH1/NAALADase I, 4234-ZN, bio-techne, USA) with some modifications using LC-MS. CPT-WT-H NPs solutions (125 μL, 0.1 mg·mL −1 in HEPS buffer) were incubated with the rh-PSMA solution (125 μL, 1.0 μg·mL −1 in HEPS buffer) at 37°C for 2 h, 8 h, 12 h, 24 h and 48 h in a remonstrated oscillator (HZQ-QX, Harbin Donglian Instrument Co. Ltd., China).

    Techniques:

    Characterization of CPT-WT-H NPs. ( A ) A TEM image of CPT-WT-H NPs dispersed in PBS (pH 7.4); inserts are the photographs of CPT-WT-H NPs in PBS in bright field (left) and under UV light at 365 nm with a red laser passing through (right). ( B ) DLS histograms of CPT-WT-H NPs in PBS. ( C ) Change of hydrodynamic diameter (Dh) of CPT-WT-H NPs in PBS for 120 h. ( D ) Schematic of sequential PSMA hydrolysis of CPT-WT-H (CPT12A-βAsp-GluγGluγGluγGlu) to yield the PSMA hydrolysate CPT12A-βAsp. ( E ) Characterization of in vitro PSMA response of CPT-WT-H NPs by LC-MS.

    Journal: International Journal of Nanomedicine

    Article Title: Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery

    doi: 10.2147/IJN.S331060

    Figure Lengend Snippet: Characterization of CPT-WT-H NPs. ( A ) A TEM image of CPT-WT-H NPs dispersed in PBS (pH 7.4); inserts are the photographs of CPT-WT-H NPs in PBS in bright field (left) and under UV light at 365 nm with a red laser passing through (right). ( B ) DLS histograms of CPT-WT-H NPs in PBS. ( C ) Change of hydrodynamic diameter (Dh) of CPT-WT-H NPs in PBS for 120 h. ( D ) Schematic of sequential PSMA hydrolysis of CPT-WT-H (CPT12A-βAsp-GluγGluγGluγGlu) to yield the PSMA hydrolysate CPT12A-βAsp. ( E ) Characterization of in vitro PSMA response of CPT-WT-H NPs by LC-MS.

    Article Snippet: The in vitro PSMA response of the CPT-WT-H NPs was performed as described in the product catalog (Recombinant Human PSMA/FOLH1/NAALADase I, 4234-ZN, bio-techne, USA) with some modifications using LC-MS. CPT-WT-H NPs solutions (125 μL, 0.1 mg·mL −1 in HEPS buffer) were incubated with the rh-PSMA solution (125 μL, 1.0 μg·mL −1 in HEPS buffer) at 37°C for 2 h, 8 h, 12 h, 24 h and 48 h in a remonstrated oscillator (HZQ-QX, Harbin Donglian Instrument Co. Ltd., China).

    Techniques: In Vitro, Liquid Chromatography with Mass Spectroscopy

    In vitro cytotoxicity of CPT-WT-H NPs and CPT against PSMA-expressing (PSMA + ) cancer cell LNCaP-FGC ( A ) and non-PSMA-expressing (PSMA − ) cancer cells HepG2 ( B ), MCF-7 ( C ), HeLa ( D ), DU145 ( E ), PC-3 ( F ) and normal liver cells LO2 ( G ), the IC 50 values of CPT and CPT-WT-H NPs on different cell lines ( H ). *** p < 0.001, vs LNCaP-FGC cells.

    Journal: International Journal of Nanomedicine

    Article Title: Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery

    doi: 10.2147/IJN.S331060

    Figure Lengend Snippet: In vitro cytotoxicity of CPT-WT-H NPs and CPT against PSMA-expressing (PSMA + ) cancer cell LNCaP-FGC ( A ) and non-PSMA-expressing (PSMA − ) cancer cells HepG2 ( B ), MCF-7 ( C ), HeLa ( D ), DU145 ( E ), PC-3 ( F ) and normal liver cells LO2 ( G ), the IC 50 values of CPT and CPT-WT-H NPs on different cell lines ( H ). *** p < 0.001, vs LNCaP-FGC cells.

    Article Snippet: The in vitro PSMA response of the CPT-WT-H NPs was performed as described in the product catalog (Recombinant Human PSMA/FOLH1/NAALADase I, 4234-ZN, bio-techne, USA) with some modifications using LC-MS. CPT-WT-H NPs solutions (125 μL, 0.1 mg·mL −1 in HEPS buffer) were incubated with the rh-PSMA solution (125 μL, 1.0 μg·mL −1 in HEPS buffer) at 37°C for 2 h, 8 h, 12 h, 24 h and 48 h in a remonstrated oscillator (HZQ-QX, Harbin Donglian Instrument Co. Ltd., China).

    Techniques: In Vitro, Expressing

    Cellular uptake of CPT-WT-H NPs in vitro. ( A ) CLSM images of LNCaP-FGC (PSMA + ) cells incubated with CPT-WT-H NPs (10 μM) for 1 and 4 h. ( B ) CLSM images of HepG2 (PSMA − ) cells incubated with CPT-WT-H NPs (10 μM) for 1 and 4 h. Nuclei were stained by PI (red), the blue color was indicative of CPT. ( C ) Mean fluorescence intensity of CPT-WT-H NPs internalized by LNCaP-FGC and HepG2 cells after incubation for 1, and 4 h. *** p < 0.001. ( D ) Flow cytometry analysis for apoptosis of LNCaP-FGC (PSMA + ) (1) and HepG2 (PSMA − ) (2) cells induced by CPT-WT-H NPs for 72 h. Q1, necrotic cells; Q2, late apoptotic cells; Q3, living cells; Q4, early apoptotic cells. Inserted numbers in the profiles indicate the percentage of the cells present in this area.

    Journal: International Journal of Nanomedicine

    Article Title: Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery

    doi: 10.2147/IJN.S331060

    Figure Lengend Snippet: Cellular uptake of CPT-WT-H NPs in vitro. ( A ) CLSM images of LNCaP-FGC (PSMA + ) cells incubated with CPT-WT-H NPs (10 μM) for 1 and 4 h. ( B ) CLSM images of HepG2 (PSMA − ) cells incubated with CPT-WT-H NPs (10 μM) for 1 and 4 h. Nuclei were stained by PI (red), the blue color was indicative of CPT. ( C ) Mean fluorescence intensity of CPT-WT-H NPs internalized by LNCaP-FGC and HepG2 cells after incubation for 1, and 4 h. *** p < 0.001. ( D ) Flow cytometry analysis for apoptosis of LNCaP-FGC (PSMA + ) (1) and HepG2 (PSMA − ) (2) cells induced by CPT-WT-H NPs for 72 h. Q1, necrotic cells; Q2, late apoptotic cells; Q3, living cells; Q4, early apoptotic cells. Inserted numbers in the profiles indicate the percentage of the cells present in this area.

    Article Snippet: The in vitro PSMA response of the CPT-WT-H NPs was performed as described in the product catalog (Recombinant Human PSMA/FOLH1/NAALADase I, 4234-ZN, bio-techne, USA) with some modifications using LC-MS. CPT-WT-H NPs solutions (125 μL, 0.1 mg·mL −1 in HEPS buffer) were incubated with the rh-PSMA solution (125 μL, 1.0 μg·mL −1 in HEPS buffer) at 37°C for 2 h, 8 h, 12 h, 24 h and 48 h in a remonstrated oscillator (HZQ-QX, Harbin Donglian Instrument Co. Ltd., China).

    Techniques: In Vitro, Incubation, Staining, Fluorescence, Flow Cytometry

    In vivo NIRF imaging of DiR-doped CPT-WT-H NPs. ( A ) In vivo NIRF images of the MCF-7 tumor-bearing nude mice (PSMA-producing) after intravenous injection of free DiR (0.25 mg·mL −1 , 100 µL) or DiR-doped CPT-WT-H NPs (0.25 mg·mL −1 , 100 µL). ( B ) Integrated fluorescence intensity of tumor obtained after intravenous injection of DiR-doped CPT-WT-H NPs (0.25 mg·mL −1 , 100 µL). ( C ) Ex vivo NIRF images and ( D ) Integrated fluorescence intensity of the major organs and tumors excised at 48 h post intravenous injection of DiR-doped CPT-WT-H NPs, *** p < 0.001, vs tumor. ( E ) In vivo pharmacokinetics profiles of CPT-WT-H NPs s at the equivalent dose (30 mg·kg −1 ) in BALB/c mice. Error bars indicate SD (n = 6).

    Journal: International Journal of Nanomedicine

    Article Title: Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery

    doi: 10.2147/IJN.S331060

    Figure Lengend Snippet: In vivo NIRF imaging of DiR-doped CPT-WT-H NPs. ( A ) In vivo NIRF images of the MCF-7 tumor-bearing nude mice (PSMA-producing) after intravenous injection of free DiR (0.25 mg·mL −1 , 100 µL) or DiR-doped CPT-WT-H NPs (0.25 mg·mL −1 , 100 µL). ( B ) Integrated fluorescence intensity of tumor obtained after intravenous injection of DiR-doped CPT-WT-H NPs (0.25 mg·mL −1 , 100 µL). ( C ) Ex vivo NIRF images and ( D ) Integrated fluorescence intensity of the major organs and tumors excised at 48 h post intravenous injection of DiR-doped CPT-WT-H NPs, *** p < 0.001, vs tumor. ( E ) In vivo pharmacokinetics profiles of CPT-WT-H NPs s at the equivalent dose (30 mg·kg −1 ) in BALB/c mice. Error bars indicate SD (n = 6).

    Article Snippet: The in vitro PSMA response of the CPT-WT-H NPs was performed as described in the product catalog (Recombinant Human PSMA/FOLH1/NAALADase I, 4234-ZN, bio-techne, USA) with some modifications using LC-MS. CPT-WT-H NPs solutions (125 μL, 0.1 mg·mL −1 in HEPS buffer) were incubated with the rh-PSMA solution (125 μL, 1.0 μg·mL −1 in HEPS buffer) at 37°C for 2 h, 8 h, 12 h, 24 h and 48 h in a remonstrated oscillator (HZQ-QX, Harbin Donglian Instrument Co. Ltd., China).

    Techniques: In Vivo, Imaging, Injection, Fluorescence, Ex Vivo

    CPT-WT-H NPs significantly inhibited tumor progression and dramatically reduced side effects in an MCF-7 human breast cancer model. ( A ) The growth curves of MCF-7 tumor after treatment, which was initiated on day 13 post tumor inoculation, and drugs were intravenously injected every 2 days for 8 times (n = 6/group). ( B ) Changes of body weight in each group. ( C ) The tumor pictures in each group. ( D ) Excised tumor weight in each group. ( E ) Excised tumor volume in each group. * p < 0.05; *** p < 0.001. ( F ) Histological analysis of tumor sections stained with H&E.

    Journal: International Journal of Nanomedicine

    Article Title: Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery

    doi: 10.2147/IJN.S331060

    Figure Lengend Snippet: CPT-WT-H NPs significantly inhibited tumor progression and dramatically reduced side effects in an MCF-7 human breast cancer model. ( A ) The growth curves of MCF-7 tumor after treatment, which was initiated on day 13 post tumor inoculation, and drugs were intravenously injected every 2 days for 8 times (n = 6/group). ( B ) Changes of body weight in each group. ( C ) The tumor pictures in each group. ( D ) Excised tumor weight in each group. ( E ) Excised tumor volume in each group. * p < 0.05; *** p < 0.001. ( F ) Histological analysis of tumor sections stained with H&E.

    Article Snippet: The in vitro PSMA response of the CPT-WT-H NPs was performed as described in the product catalog (Recombinant Human PSMA/FOLH1/NAALADase I, 4234-ZN, bio-techne, USA) with some modifications using LC-MS. CPT-WT-H NPs solutions (125 μL, 0.1 mg·mL −1 in HEPS buffer) were incubated with the rh-PSMA solution (125 μL, 1.0 μg·mL −1 in HEPS buffer) at 37°C for 2 h, 8 h, 12 h, 24 h and 48 h in a remonstrated oscillator (HZQ-QX, Harbin Donglian Instrument Co. Ltd., China).

    Techniques: Injection, Staining

    Representative H&E-stained histological images obtained from liver ( A ) and kidneys ( B ) after intravenous administration of irinotecan (10 mg·kg −1 ) and CPT-WT-H NPs (10, 30, 60 mg·kg −1 ). The PBS-treated group and the untreated group were used as the control. (I: PBS, II: CPT-WT-H NPs (10mg·kg −1 ), III: CPT-WT-H NPs (30mg·kg −1 ), IV: CPT-WT-H NPs (60mg·kg −1 ), V: Irinotecan (10 mg·kg −1 ), VI: Normal group). ( C ) Blood biochemical analysis of after the antitumor efficacy evaluation. The PBS-treated group and the untreated group were used as the control. The main parameters of hepatic and renal function are alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), and creatinine (CRE). Error bars indicate SD (n = 6). * p < 0.05; *** p < 0.001.

    Journal: International Journal of Nanomedicine

    Article Title: Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery

    doi: 10.2147/IJN.S331060

    Figure Lengend Snippet: Representative H&E-stained histological images obtained from liver ( A ) and kidneys ( B ) after intravenous administration of irinotecan (10 mg·kg −1 ) and CPT-WT-H NPs (10, 30, 60 mg·kg −1 ). The PBS-treated group and the untreated group were used as the control. (I: PBS, II: CPT-WT-H NPs (10mg·kg −1 ), III: CPT-WT-H NPs (30mg·kg −1 ), IV: CPT-WT-H NPs (60mg·kg −1 ), V: Irinotecan (10 mg·kg −1 ), VI: Normal group). ( C ) Blood biochemical analysis of after the antitumor efficacy evaluation. The PBS-treated group and the untreated group were used as the control. The main parameters of hepatic and renal function are alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), and creatinine (CRE). Error bars indicate SD (n = 6). * p < 0.05; *** p < 0.001.

    Article Snippet: The in vitro PSMA response of the CPT-WT-H NPs was performed as described in the product catalog (Recombinant Human PSMA/FOLH1/NAALADase I, 4234-ZN, bio-techne, USA) with some modifications using LC-MS. CPT-WT-H NPs solutions (125 μL, 0.1 mg·mL −1 in HEPS buffer) were incubated with the rh-PSMA solution (125 μL, 1.0 μg·mL −1 in HEPS buffer) at 37°C for 2 h, 8 h, 12 h, 24 h and 48 h in a remonstrated oscillator (HZQ-QX, Harbin Donglian Instrument Co. Ltd., China).

    Techniques: Staining